Complement activation induces excessive T cell cytotoxicity in severe COVID-19

Basic information
Sample
49

Technology
10X Genomics
Omics
scRNA-seq
Source
PBMCs

Dataset ID
35032429
Platform
Illumina NovaSeq 6000
Species
Human
Disease
COVID-19,Healthy
Age range
21 - 90
Update date
2022-02-03
Summary

Severe COVID-19 is linked to both dysfunctional immune response and unrestrained immunopathology, and it remains unclear whether T cells contribute to disease pathology. Here, we combined single-cell transcriptomics and single-cell proteomics with mechanistic studies to assess pathogenic T cell functions and inducing signals. We identified highly activated CD16+ T cells with increased cytotoxic functions in severe COVID-19. CD16 expression enabled immune-complex-mediated, T cell receptor-independent degranulation and cytotoxicity not found in other diseases. CD16+ T cells from COVID-19 patients promoted microvascular endothelial cell injury and release of neutrophil and monocyte chemoattractants. CD16+ T cell clones persisted beyond acute disease maintaining their cytotoxic phenotype. Increased generation of C3a in severe COVID-19 induced activated CD16+ cytotoxic T cells. Proportions of activated CD16+ T cells and plasma levels of complement proteins upstream of C3a were associated with fatal outcome of COVID-19, supporting a pathological role of exacerbated cytotoxicity and complement activation in COVID-19.

Overall design

Blood from 19 COVID-19 patients at acute and convalescent (for 13 patients) phases for mild-moderate (9 patients) and severe (10 patients), from 6 healthy controls as well as from 8 patients with flu-like disease and 4 patients with chronic HBV infection was collected and PBMC prepared.

Contributors

To be supplemented.

Contact

To be supplemented.

snRNA-Seq
Sample nameSample titleDiseaseGenderAgeSourceTreatmentTechnologyPlatformOmicsSample IDDataset IDAction
No data available